Sandoz receives European Commission approval for biosimilar Hyrimoz (adalimumab)
- Biosimilar Hyrimoz(adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology
- Early therapeutic intervention is essential in rheumatoid arthritis, supporting urgency of treatments like Hyrimoz
- Fourth Sandoz biosimilar approved in Europe** in past 18 months, and seventh in total, underscoring Sandoz commitment to making access happen through a robust portfolio
# # #
Novartis Media Relations Central media line: +41 61 324 2200 E-mail: media.relations@novartis.comEric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com | |
Chris Lewis Sandoz Global Communications +49 174 244 9501 (mobile) chris.lewis@sandoz.com | Michelle Bauman Sandoz Global Communications ++1 973 714 8043 (mobile) michelle.bauman@sandoz.com |